Clarus Therapeutics Holdings, Inc. CRXT
We take great care to ensure that the data presented and summarized in this overview for Clarus Therapeutics Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in CRXT
Top Purchases
Top Sells
About CRXT
Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.
Insider Transactions at CRXT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2022
|
Elizabeth Cermak Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,922
+25.0%
|
-
|
|
Jun 07
2022
|
Joseph Hernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,922
+0.15%
|
-
|
|
Jun 07
2022
|
John Kenneth Amory Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,922
+25.0%
|
-
|
|
Jun 07
2022
|
Kimberly M Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,922
+25.0%
|
-
|
|
Jun 07
2022
|
Mark A Sr Prygocki Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,922
+25.0%
|
-
|
|
Apr 25
2022
|
Joseph Hernandez Director |
BUY
Other acquisition or disposition
|
Direct |
1,237,500
+49.92%
|
-
|
|
Apr 25
2022
|
Joseph Hernandez Director |
SELL
Other acquisition or disposition
|
Indirect |
65,000
-4.99%
|
-
|
|
Dec 12
2021
|
Kimberly M Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,844
+50.0%
|
-
|
|
Dec 12
2021
|
Joseph Hernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,844
+50.0%
|
-
|
|
Dec 12
2021
|
Robert E. Dudley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
135,000
+49.17%
|
-
|
|
Dec 12
2021
|
John Kenneth Amory Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,844
+50.0%
|
-
|
|
Dec 12
2021
|
Elizabeth Cermak Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,844
+50.0%
|
-
|
|
Dec 12
2021
|
Mark A Sr Prygocki Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,844
+50.0%
|
-
|
|
Dec 11
2021
|
Steven A. Bourne Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+48.9%
|
-
|
|
Dec 11
2021
|
Richard D Peterson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,800
+50.0%
|
-
|
|
Dec 11
2021
|
Frank Jaeger Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
29,000
+50.0%
|
-
|
|
Sep 17
2021
|
Ffi Fund LTD > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
127,360
-5.71%
|
$1,146,240
$9.2 P/Share
|
|
Sep 09
2021
|
H.I.G. Ventures Clarus, LLC > 10% Shareholder |
BUY
Grant, award, or other acquisition
|
Indirect |
5,692,381
+50.0%
|
-
|
|
Sep 09
2021
|
Steven A. Bourne Chief Administrative Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,305
+50.0%
|
-
|
|
Sep 09
2021
|
Robert E. Dudley Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,566
+50.0%
|
-
|